Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 4,540,000 shares, a drop of 9.9% from the January 15th total of 5,040,000 shares. Approximately 18.5% of the shares of the company are sold short. Based on an average daily volume of 429,700 shares, the days-to-cover ratio is presently 10.6 days.

Arcturus Therapeutics Stock Down 2.3 %

ARCT traded down $0.39 during trading on Thursday, reaching $16.93. 356,654 shares of the company's stock were exchanged, compared to its average volume of 418,484. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The business has a 50 day moving average price of $16.97 and a 200 day moving average price of $18.86. The company has a market capitalization of $458.63 million, a P/E ratio of -7.63 and a beta of 2.62.

Analyst Ratings Changes

A number of equities analysts have recently commented on ARCT shares. HC Wainwright reissued a "buy" rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Finally, BTIG Research began coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $41.00 price target on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $65.00.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Woodline Partners LP boosted its stake in Arcturus Therapeutics by 3.5% during the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock worth $13,693,000 after buying an additional 26,956 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Arcturus Therapeutics by 60.9% in the 4th quarter. Two Sigma Investments LP now owns 27,560 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 10,430 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at $200,000. MPM Bioimpact LLC boosted its stake in shares of Arcturus Therapeutics by 109.5% in the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock valued at $7,805,000 after purchasing an additional 240,435 shares in the last quarter. Finally, J. Goldman & Co LP acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at $5,024,000. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.